Pharvaris N.V. (NASDAQ:PHVS) Stock Has Consensus Price Target of $59.87

Key Points

• Analysts maintain a broadly positive outlook: Pharvaris has a “Moderate Buy” consensus from 15 analysts, with 13 buy ratings and an average 12-month price target of $59.87, well above its $31.91 opening price.
• The company reported weaker-than-expected quarterly results: Pharvaris posted an adjusted loss of $0.81 per share versus the $0.75 consensus estimate, and analysts expect a full-year loss of approximately $3.12 per share.
• Insider selling was significant: Company insiders sold 513,102 shares worth about $18.6 million over the last quarter, including sizable sales by President Peng Lu and Director Elisabeth Bjork.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fifteen analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $59.87.

A number of brokerages recently weighed in on PHVS. Oppenheimer reaffirmed an "outperform" rating and set a $75.00 price objective on shares of Pharvaris in a research report on Tuesday, September 8th. Wall Street Zen downgraded shares of Pharvaris from a "hold" rating to a "sell" rating in a report on Saturday, July 18th. Citizens Jmp raised their price target on shares of Pharvaris from $75.00 to $79.00 and gave the company a "market outperform" rating in a report on Wednesday, September 9th. Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a research report on Wednesday, September 9th. Finally, UBS Group set a $79.00 price objective on shares of Pharvaris in a research note on Wednesday, September 9th.

Pharvaris Stock Down 0.3%

Shares of PHVS stock opened at $31.91 on Tuesday. The company's 50 day moving average is $35.26 and its 200 day moving average is $32.06. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -10.46 and a beta of -2.33. Pharvaris has a 52-week low of $20.65 and a 52-week high of $43.25.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Analysts anticipate that Pharvaris will post -3.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Pharvaris news, President Peng Lu sold 100,000 shares of Pharvaris stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total value of $3,500,000.00. Following the transaction, the president directly owned 64,953 shares of the company's stock, valued at approximately $2,273,355. The trade was a 60.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elisabeth Bjork sold 52,500 shares of the company's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $37.89, for a total value of $1,989,225.00. Following the transaction, the director directly owned 15,167 shares in the company, valued at approximately $574,677.63. The trade was a 77.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 513,102 shares of company stock valued at $18,643,666 over the last quarter.

Institutional Investors Weigh In On Pharvaris

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. increased its holdings in shares of Pharvaris by 225.5% during the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company's stock valued at $14,068,000 after acquiring an additional 281,829 shares in the last quarter. BlackRock Inc. acquired a new stake in Pharvaris in the 2nd quarter worth approximately $26,677,000. Seven Fleet Capital Management LP grew its position in Pharvaris by 144.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company's stock worth $26,782,000 after purchasing an additional 457,804 shares during the last quarter. Wellington Management Group LLP grew its position in Pharvaris by 12.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock worth $82,748,000 after purchasing an additional 274,034 shares during the last quarter. Finally, Moore Capital Management LP purchased a new stake in Pharvaris during the 2nd quarter worth approximately $1,522,000.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.